The executive director in translational medicine at a major pharmaceutical company discusses how their company invests in various technologies and sees consequent returns on these investments. This expert works in a role that takes biomarker strategies from early discovery through registrational trials. Despite being considered a more novel or “risky” technology, cellomics is a main point of investment at this expert’s organization, along with bioinformatics, and companion diagnostics. Currently, they see the greatest ROI in companion diagnostics, clinical trial operations, and bioinformatics. This expert believes proteomics have not yet lived up to its clinical potential, and that the cost of data offered by in vitro models is becoming harder to justify. They will continue to make investment decisions that not only reduce development timelines and increase discovery productivity, but also allow for diversification of the pipeline. A trend, and pain point, that this expert is particularly cognizant of is the FDA’s Optimus Act, which relates to how pharma establishes dosages for their products; they also see the increasing regulations on diagnostic tools (e.g., IVDR) and emerging therapeutic modalities as being pivotal trends in the oncology landscape.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.